CHEK1 and Fanconi anemia: Considerable evidence is now available suggesting that loss of one or several key genes involved in HR, among these ATM, CHEK1/2, NBN, RAD51 and genes of the Fanconi Anemia complementation group, is associated with sensitivity of cancers to platinum drugs and PARP inhibitors.